Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Pasithea Therapeutics Corp
Healthcare
P/NCAV
0.62x
Ticker
KTTA
Exchange
NASDAQ
Country
United States
Close
7.09 $
Mkt Cap
8.7M $
EV
-7.6M $
NCAV Burn Rate
55.5%
Current Ratio
6.34
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.5x
EV/FCF
0.6x
Dilution
23.4% p.A
Total Net Income
-32.1M $
Cheapness
100.0%
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average